Back to search
Tumor Infiltrating Lymphocytes
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Tumor Infiltrating Lymphocytes trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Tumor Infiltrating Lymphocytes trials you may qualify forBackground: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the labo…
Background: Cell therapy is an experimental cancer therapy. It takes young tumor infiltrating lymphocytes (Young TIL) cells from a person s tumors and grows th…
Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the labo…
This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
Expected to complete 7 to 18 evaluable subjects (patients with advanced solid tumors)，3 dose groups.A modified "3+3" dose-escalation design is utilized,This inc…
This study is a single-arm early exploratory clinical study. designed to evaluate the safety and tolerability of GT201 in combination with a PD-1 inhibitor for…
Background: Many advances have been made in cancer treatments, but more research is needed. Comparing samples of cancerous tissue to samples of normal, noncanc…
This phase II trial tests how well lifileucel, with reduce dose fludarabine and cyclophosphamide for lymphodepletion and interleukin-2, work for treating patien…
28 participants are expected to be enrolled for the Phase II clinical trial, this trial is expected to be finished in 36 months.